Raiffeisen Bank International AG Acquires Shares of 30,644 Johnson & Johnson (NYSE:JNJ)

Raiffeisen Bank International AG bought a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 30,644 shares of the company's stock, valued at approximately $4,393,000.

Several other large investors also recently bought and sold shares of JNJ. Sulzberger Capital Advisors Inc. purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at $453,000. Oregon Pacific Wealth Management LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at $949,000. Horan Securities Inc. boosted its holdings in Johnson & Johnson by 1.3% during the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock worth $1,038,000 after buying an additional 90 shares in the last quarter. Strategic Financial Concepts LLC boosted its holdings in Johnson & Johnson by 57.9% during the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock worth $501,000 after buying an additional 1,271 shares in the last quarter. Finally, KPP Advisory Services LLC boosted its holdings in Johnson & Johnson by 4.7% during the fourth quarter. KPP Advisory Services LLC now owns 11,492 shares of the company's stock worth $1,662,000 after buying an additional 515 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded up $1.76 during mid-day trading on Friday, reaching $151.37. The company's stock had a trading volume of 8,045,511 shares, compared to its average volume of 7,949,399. The stock has a 50-day moving average of $156.27 and a two-hundred day moving average of $153.90. The stock has a market capitalization of $364.20 billion, a P/E ratio of 22.76, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a $1.30 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.44%. Johnson & Johnson's payout ratio is presently 57.84%.

Insider Activity

In related news, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on JNJ. Stifel Nicolaus lowered their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a report on Thursday, January 23rd. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Raymond James lowered their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Finally, Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.